Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145327 · ClinicalTrials.gov registry record · Phase 3
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
A Phase 3 study of Osteoporosis, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,456
- Enrollment target
- 20
- Study locations
NCT00145327 is a Phase 3 study of Osteoporosis that has completed, run by Novartis. The registered enrollment target is 2,456 participants, above the 1,517-participant average among 84 other Osteoporosis trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00145327, a Phase 3 study of Osteoporosis, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,456 participants
- Enrollment target
- 20
- Study locations
Study Summary
This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is the same as Year 3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zoledronic Acid
Study Locations (20)
California
- Osteoporosis Medical Center - Beverly Hills
- Osteoporosis Prevention Center - San Diego
- Diablo Clinical Research, Inc - Walnut Creek
Florida
- CRIA Research - Fort Lauderdale
- Radiant Research - Stuart
- Comprehensive Clinical Trials, LLC - West Palm Beach
Indiana
- School of Medicine - Indianapolis
- Medical Specialist Clinical Research Center - Munster
Arizona
- Southern Arizona VA - Tucson
Arkansas
- University of Arkansas for Medical Science - Little Rock
Colorado
- Colorado Center for Bone Research - Lakewood
Georgia
- United Osteoporosis Centers (UOC) - Gainesville
Illinois
- Northwestern University Center for Clinical Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,456 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145327
The ClinicalTrials.gov registry entry for NCT00145327 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,456 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,517-participant average among 84 other Osteoporosis trials with a reported enrollment target (62% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00145327 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00145327 about?
NCT00145327 is a clinical study titled "Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)". This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is...
What is the current status of trial NCT00145327?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,456 participants. The study started on 2005-05. Estimated completion is 2009-11.
What conditions does trial NCT00145327 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00145327?
The interventions under investigation include: Placebo (DRUG), Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00145327?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00145327 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
COMPLETED · Phase 3
-
Secondary Prevention of Osteoporosis
COMPLETED · Phase 3
-
HORIZON-PFT: Pivotal Fracture Trial
COMPLETED · Phase 3
-
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.